Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICT 107

Drug Profile

ICT 107

Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107

Latest Information Update: 18 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Suspended Glioblastoma

Most Recent Events

  • 08 May 2019 ImmunoCellular Therapeutics and Unknown company entered into a asset purchase agreement for ICT 107, ICT 140, ICT 121 and stem-to-T-cell research programme preclinical asset
  • 21 Jun 2017 ICT 107 is available for licensing as of 21 Jun 2017. www.imuc.com
  • 21 Jun 2017 Suspended upon strategic review of financing and development strategies for ICT 107 - Phase-III for Glioblastoma (Combination therapy, First-line therapy) in Canada, USA, Austria, Germany, Netherlands and Spain (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top